A notable proportion of network hubs—including FXR, GPBAR1, IL6, and TNF—were shared across multiple disease pathways, emphasizing the relevance of probiotic metabolites in modulating conditions such as type 2 diabetes, obesity, NAFLD, and IBD. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.